The syntheses and preliminary in vitro microbiological properties of 1-N-(S-4-amino-2-hydroxybutyryl)-and I -N-(S-3-ami no-2-hyd roxypropionyl)-deri vat ives of gentamicin CIII and gentamicin C,,,a' were published from our laboratory. In this paper we present the syntheses of the analogous gentamicin B derivatives and discuss their microbiological properties.
Gentamicin B is 4-0-(6-amino-6-deoxy-x-D-glucopyranosyl)-garamine (1)3" and is coproduced in the gentamicin fermentation'). Its close structural relationship with kanamycin A (2) prompted us to synthesize the 1-N-(S-4-amino-2-hydroxybutyryl)-and 1-N-(S-3-amino-2-hydroxypropionyl)-derivatives (Sch 20287 and Sch 21420, respectively) to compare their biological properties with amikacin, the I -N-(S-4-amino-2-hydroxybutyryl)-derivative of kanamycin A (3)"') As illustrated in Scheme 1, the conversion of gentamicin B (1) to Sch 20287 and Sch 21420 was accomplished following the procedure of KAWAGUCHI and co-workers') for the synthesis of amikacin (3) from kanamycin A (2) . The condensation of 6'-N-tert-butoxycarbonyl-gentamicin B (4) with N-(S-4-benzyloxycarbonylamino-2-hydroxybutyryloxy)-succinimidel,',1) afforded a mixture of products from which the desired I-N-(S-4-benzyloxycarbonylamino-2-hydroxybutyryl)-6'-N-tert-butoxycarbonyl To whom inquiries should be addressed.
gentamicin B (5) was isolated by chromatography as a mixture with its 3-isomer (7). Similar results were obtained when compound (4) was condensed with N-(S-3-benzyloxycarbonylamino-2-hydroxypropionyloxy)-succinimidel"2). However, in this case, the desired condensation product (6) could be separated from its 3 isomer (8) . After removal of the benzyloxycarbonyl group by catalytic hydrogenation, the 1-N-(S-4-amino-2-hydroxybutyryl)-6'-N-tert-butoxycarbonyl-gentamicin B (9) could be separated from the 3-isomer (10) by column chromatography. Catalytic hydrogenation of compound 6 afforded compound (11), the analogous 1-N-propionyl derivative. Removal of the tert-butoxycarbonyl protecting groups of (9) and (11) with trifluoroacetic acid and deionization led to the desired compounds, Sch 20287 and Sch 21420, respectively.
Confirmation of the structures of Sch 20287 and Sch 21420 was obtained from a study of the proton magnetic resonance and proton-decoupled carbon-13 magnetic resonance spectra of these two compounds and amikacin in basic and acidic media. In Table 1 due to protonation of both the 1-and the 3-amino groups on adjacent carbon atoms. In contrast to C6, the C4 nucleus of kanamycin A (86.8 ppm) experiences a much larger upfield shift on protonation, the magnitude of which is nearly twice that of C6 although there is only one amino group in the /?-position. Also notable is the fact that C1' of kanamycin A, which does not have an amino group in the /3-position, undergoes an upfield shift of 3.2 ppm on protonation of the amino groups elsewhere in the molecule. Consistent with the structure, protonation of amikacin causes an upfield shift of C2 of only 4.2 ppm as compared to protonation of kanamycin A which causes an upfield shift of C2 of 7.6 ppm indicating substitution at one of the deoxystreptamine nitrogens by the acyl side chain. The fact that C6 of amikacin undergoes no acid shift and C4 still maintains the unexpectedly large shielding (7.8 ppm) on protonation found in kanamycin A confirms that the acyl side chain in amikacin is at the I-position. As in kanamycin A, the "non /3-amino-protonation shielding" of CI' is still observed in amikacin. Furthermore, like in kanamycin A, the nuclei C5', C2", and C4" of amikacin show the expected upfield shifts on protonation confirming the presence of amino groups at C6' and C3". Finally, Sch 21420 and amikacin had identical spectra of activity against gentamicin-resistant
Gram-negative organisms containing various aminoglycoside N-acetylating enzymes. These results are shown in Table 4 .
In potency, Sch 21420 was equi-active or slightly more potent than amikacin against strains of Proteus rettgeri and Serratia containing N-acetylating enzymes. Against strains of P. aeruginosa containing N-acetylating enzymes, Sch 21420 was equal to, or slightly less active than amikacin. Against Providencia strains possessing [AAC (2')] enzymes, amikacin was slightly more active.
Detailed biology of Sch 21420 is described in the accompanying paper 12
Experimental
Details of experimental techniques have been published in our earlier papers"') 6'-N-tert-Butoxycarbonylgentamicin B (4) To a stirred solution of gentamicin B (1) (1 g, 2.07 mmol) in 50% aqueous methanol (30 ml) at 5°C was added tert-butoxycarbonyl azide (0.297 g, 2.26 mmol) in a dropwise manner. Triethylamine (0.186 ml) was added next and the solution stirred for 18 hours at room temperature. The solution was concentrated to dryness in vacuo and the residue chromatographed on a column of silica gel (60-200 mesh) (100 g) using the lower phase of a solvent mixture consisting of chloroform, methanol and ammonium hydroxide The mass spectrum of a sample of 4 which had been per-N-acetylated and treated with trifluoroacetic acid to de-1V-protect the tert-butoxycarbonyl group followed by de-ionization showed a strong To a stirred solution of 6'-N-tert-butoxycarbonylgentamicin B (4) (2.34g, 4mmol) in water (10 ml) was added methanol (30 ml) and the mixture was cooled to about 5°C. A solution of N-(S-4-benzyloxycarbonylamino-2-hydroxybutyryloxy)-succinimidel'2 (2.71 g, 7.75 mmol) in dimethyl formamide (12 ml) was added dropwise. After 5 hours at 5°C, the solution was concentrated to dryness in vacxro and the residue chromatographed on silica gel (60 -200 mesh, 250 g) using a solvent mixture composed of chloroform, methanol and ammonium hydroxide (30 : 10 : 1) as the eluant. Fractions 691-1200 were pooled, concentrated and dried to give 1.99 g of mixture of 1-N-and 3-N-(S-4-benzyloxycarbonylamino-2-hydroxy)-6'-N-tert-butoxycarbonylgentamicin B (5 and 7). The mixture containing 5 and 7 was dissolved in water (120 ml) and methanol (48 ml), and hydrogenated in the presence of 5 % palladium-oncarbon catalyst (0.3 g) at 50 p.s.i for 3 hours. The catalyst was removed by filtration and the filtrate which showed two spots on TLC examination was concentrated to dryness (1.7 g) and the residue chromatographed on 100 g silica gel using a solvent system composed of chloroform, methanol, ammonium hydroxide (2 : Found: C, 41.62; H, 7.42; N, 10.28 %. Fractions 100 125 contained the 3-N-isomer of 9 which when processed as above gave biologically inactive material I-N-(S-3-Amino-2-hydroxypropionyl)-gentamicin B (Sch 21420) This compound was prepared from 4 in a manner similar to that described above for Sch 20287. Thus, 6'-N-tent-butoxycarbonylgentamicin B (4) (2.34g, 4.02 mmol) was treated with N-(S-3-benzyloxycarbonylamino-2-hydroxypropionyloxy)-succinimide (2.6 g, 7.75 mmol) to obtain a crude product which was chromatographed on silica gel (250 g) using chloroform-methanol-ammonium hydroxide (30:10:1) as the eluant. Work-up of fractions 420 735 as in the above experiment gave 0.913 g of pure 1-N-(S-3-benzyloxycarbon),lamino-2-hydroxypropionyl)-6'-N-tent-butoxycarbonylgentamicin B (6) which was hydrogenated and the product de-N-protected with trifluoroacetic acid as described above to obtain the desired I-N-(S-3-amino-2-hydroxypropionyl)-gentamicin B as the trifluoroacetic acid salt (0.86 g). Further purification and deionization on a column of silica gel (25 g) using chloroformmethanol -ammonium hydroxide (I : 1.5 : 1) as eluant gave pure Sch 21420 (0.352 g) which was converted into the sulfate salt in the usual manner, 110.9' (c 1, water). PMR (Ds0)8 1.35 ppm (3H, s, C-CHs), 2.89 (3H, s, N-CH;), 4.47 (1H, dd, J'-4.5 Hz, 7.5 Hz, H2"'), 5. 
